Reviews on Long COVID: A scope of the literature: Update January 2024

Claire Louise Khouja; Gary Austin Raine; Melissa Harden; Katy Sutcliffe; Amanda Jayne Sowden

Reviews on Long COVID: A scope of the literature: Update January 2024

Claire Louise Khouja, Gary Austin Raine, Melissa Harden, Katy Sutcliffe, Amanda Jayne Sowden

Centre for Reviews and Dissemination

Research output: Book/Report › Commissioned report

Abstract

• For this update, we identified 42 published reviews and 42 review protocols for Long COVID. The number of published reviews Is less than in October (n=46) but more than in July (n=31) and April (n=37), 2023.
• Most published reviews were focused on the prevalence of symptoms or effects (18/42), which remains consistent with the earlier reports.
• This update includes more published reviews with a primary focus on Long COVID risk factors (n=9) than in each of the previous reports. We identified fewer on treatment or rehabilitation (n=7) than in the October 2023 report (n=11), but more than in the four previous reports (n=5).
• We identified fewer reviews on pathobiology or mechanisms (n=2), than for the October 2023 report (n=6), but a similar number to previous reports (e.g., July 2023, n=1).
• Similar numbers of protocols were focused on the prevalence of symptoms or effects (15/42), and treatment or rehabilitation (13/42). These have consistently been the largest two categories across all the previous reports.
• Seven protocols were focused on risk factors with or without prevalence; the same number as in the October 2023 report.

Original language	English
Place of Publication	London
Publisher	EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.
Commissioning body	NIHR Policy Research Programme
Number of pages	33
ISBN (Print)	978-1-911605-53-9
Publication status	Published - 14 Mar 2024

Bibliographical note

Access to Document

Review_update_Jan24_LO-140324
© Copyright 2024. Authors of the systematic reviews on the EPPI Centre website (http://eppi.ioe.ac.uk/) hold the copyright for the text of their reviews. The EPPI Centre owns the copyright for all material on the website it has developed, including the contents of the databases, manuals, and keywording and data-extraction systems. The centre and authors give permission for users of the site to display and print the contents of the site for their own non-commercial use, providing that the materials are not modified, copyright and other proprietary notices contained in the materials are retained, and the source of the material is cited clearly following the citation details provided. Otherwise, users are not permitted to duplicate, reproduce, re-publish, distribute, or store material from this website without express written permission.
Final published version, 1.37 MBLicence: CC BY-NC

Cite this

@book{20ae4e7d49954bfd9051f74f1c678ce2,

title = "Reviews on Long COVID: A scope of the literature: Update January 2024",

abstract = "• For this update, we identified 42 published reviews and 42 review protocols for Long COVID. The number of published reviews Is less than in October (n=46) but more than in July (n=31) and April (n=37), 2023.• Most published reviews were focused on the prevalence of symptoms or effects (18/42), which remains consistent with the earlier reports. • This update includes more published reviews with a primary focus on Long COVID risk factors (n=9) than in each of the previous reports. We identified fewer on treatment or rehabilitation (n=7) than in the October 2023 report (n=11), but more than in the four previous reports (n=5).• We identified fewer reviews on pathobiology or mechanisms (n=2), than for the October 2023 report (n=6), but a similar number to previous reports (e.g., July 2023, n=1).• Similar numbers of protocols were focused on the prevalence of symptoms or effects (15/42), and treatment or rehabilitation (13/42). These have consistently been the largest two categories across all the previous reports.• Seven protocols were focused on risk factors with or without prevalence; the same number as in the October 2023 report.",

author = "Khouja, {Claire Louise} and Raine, {Gary Austin} and Melissa Harden and Katy Sutcliffe and Sowden, {Amanda Jayne}",

year = "2024",

month = mar,

day = "14",

language = "English",

isbn = "978-1-911605-53-9",

publisher = "EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.",

}

TY - BOOK

T1 - Reviews on Long COVID: A scope of the literature

T2 - Update January 2024

AU - Khouja, Claire Louise

AU - Raine, Gary Austin

AU - Harden, Melissa

AU - Sutcliffe, Katy

AU - Sowden, Amanda Jayne

PY - 2024/3/14

Y1 - 2024/3/14

N2 - • For this update, we identified 42 published reviews and 42 review protocols for Long COVID. The number of published reviews Is less than in October (n=46) but more than in July (n=31) and April (n=37), 2023.• Most published reviews were focused on the prevalence of symptoms or effects (18/42), which remains consistent with the earlier reports. • This update includes more published reviews with a primary focus on Long COVID risk factors (n=9) than in each of the previous reports. We identified fewer on treatment or rehabilitation (n=7) than in the October 2023 report (n=11), but more than in the four previous reports (n=5).• We identified fewer reviews on pathobiology or mechanisms (n=2), than for the October 2023 report (n=6), but a similar number to previous reports (e.g., July 2023, n=1).• Similar numbers of protocols were focused on the prevalence of symptoms or effects (15/42), and treatment or rehabilitation (13/42). These have consistently been the largest two categories across all the previous reports.• Seven protocols were focused on risk factors with or without prevalence; the same number as in the October 2023 report.

AB - • For this update, we identified 42 published reviews and 42 review protocols for Long COVID. The number of published reviews Is less than in October (n=46) but more than in July (n=31) and April (n=37), 2023.• Most published reviews were focused on the prevalence of symptoms or effects (18/42), which remains consistent with the earlier reports. • This update includes more published reviews with a primary focus on Long COVID risk factors (n=9) than in each of the previous reports. We identified fewer on treatment or rehabilitation (n=7) than in the October 2023 report (n=11), but more than in the four previous reports (n=5).• We identified fewer reviews on pathobiology or mechanisms (n=2), than for the October 2023 report (n=6), but a similar number to previous reports (e.g., July 2023, n=1).• Similar numbers of protocols were focused on the prevalence of symptoms or effects (15/42), and treatment or rehabilitation (13/42). These have consistently been the largest two categories across all the previous reports.• Seven protocols were focused on risk factors with or without prevalence; the same number as in the October 2023 report.

M3 - Commissioned report

SN - 978-1-911605-53-9

BT - Reviews on Long COVID: A scope of the literature

PB - EPPI-Centre, Social Science Research Unit, UCL Institute of Education, University College London.

CY - London

ER -